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Research
Epigenetics can be defined broadly as the study 
of the temporal and spatial regulation of gene 
expression. Changes in epigenetic marks can 
be as profound as DNA sequence mutations, 
but unlike DNA mutations, epigenetic marks 
are reversible and responsive to the environ­
ment (Baccarelli and Bollati 2009). DNA 
methylation is the best studied of the epige­
netic processes that regulate gene expression. 
DNA methylation typically occurs in cyto­
sines within CpG repeat sequences found in 
gene promoter regions. Areas enriched in CpG 
repeats are frequently referred to as “CpG 
islands.” Methylation of DNA within pro­
moter regions regulates local gene transcrip­
tion. In general, increased DNA methylation 
is inversely associated with gene expression. 
Much epigenetic research has been focused 
on the heritability of pheno  typic traits not 
attributable to alterations in DNA sequence, 
but such epigenetic modifications would have 
to occur in germ cells to be truly heritable. 
Changes in epigenetic marks in somatic cells 
are also of great interest, as these changes can 
also be induced by environmental exposures 
and may play a role in the toxicity of environ­
mental agents, even if they are not heritable.
Previous research in both animals and 
humans has noted that DNA methylation 
can be altered by exposure to environmen­
tal metals (Reichard et al. 2007; Sciandrello 
et al. 2004; Takiguchi et al. 2003). Oxidative 
stress may be a unifying process to explain 
these findings across different metals. Metals 
are known to increase production of reactive 
oxygen species in a catalytic fashion via redox 
cycling (Fowler et al. 2004; Valko et al. 2005). 
Oxidative DNA damage can interfere with 
the ability of methyltransferases to interact 
with DNA (Turk et al. 1995; Valinluck et al. 
2004), thus resulting in a generalized hypo­
methylation of cytosine residues at CpG sites 
(Turk et al. 1995). Long­term exposure to 
oxidative stress has been shown to result in 
oxidative damage of methylated cytosine resi­
dues and depletion in the level of 5­methyl­
cytosine in repeated elements (Pogribny et al. 
2007; Valinluck et al. 2004). Lead is among 
the most prevalent of toxic environmental 
metals, has substantial oxidative properties, 
and could also alter epigenetic marks after 
long­term exposure. 
DNA methylation can be meas  ured 
both in specific genes and using global DNA 
methylation markers such as repetitive DNA 
sequences (Bollati et al. 2007; Kazazian and 
Moran 1998; Pilsner et al. 2007; Roman­
Gomez 2005). Measures of global methylation 
typically involve methylation within repetitive 
DNA sequence. The two primary types of 
repetitive elements studied are Alu and long 
interspersed nucleo  tide elements (LINE­1) 
(Bollati et al. 2007; Issa 2002; Pilsner et al. 
2007). There are approxi  mately 1.4 million 
Alu repetitive elements in the human genome 
and half a million LINE­1 elements. LINE­1 
and Alu are sometimes referred to as “junk” 
DNA. They are remnants of viral DNA 
(transposons) or viral RNA (retrotranspo­
sons) that were incorporated into the human 
genome over evolutionary history (Carnell 
and Goodman 2003; Wallace et al. 2008a, 
2008b). If transcribed, such elements can 
reinsert into DNA, potentially moving across 
the genome. These elements are rich in CpG 
repeats and are typically highly methylated 
in order to suppress their expression (Schulz 
et al. 2006). Because such elements represent 
approximately half of all DNA sequences, 
changes in methylation in LINE­1 and Alu are 
believed to be indicative of global or genomic 
methylation (Bestor and Tycko 1996; Klose 
and Bird 2006).
In this study, we analyzed global DNA 
methylation markers (Alu and LINE­1) in 
a cohort of elderly men who have been well 
characterized for their environmental cumula­
tive exposure to lead. Because of the stable, 
yet modifiable nature of DNA methylation, 
we hypothesized that bone lead, a marker of 
cumulative exposure with a half­life measured 
in years, would be associated with changes 
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Ba c k g r o u n d: DNA methylation is an epigenetic mark that regulates gene expression. Changes in 
DNA methylation within white blood cells may result from cumulative exposure to environmental 
metals such as lead. Bone lead, a marker of cumulative exposure, may therefore better predict DNA 
methylation than does blood lead.
oB j e c t i v e: In this study we compared associations between lead biomarkers and DNA methylation.
Me t h o d s : We measured global methylation in participants of the Normative Aging Study (all men) 
who had archived DNA samples. We measured patella and tibia lead levels by K-X-Ray fluorescence 
and blood lead by atomic absorption spectrophotometry. DNA samples from blood were used to 
determine global methylation averages within CpG islands of long interspersed nuclear elements-1 
(LINE-1) and Alu retrotransposons. A mixed-effects model using repeated measures of Alu or 
LINE-1 as the dependent variable and blood/bone lead (tibia or patella in separate models) as the 
primary exposure marker was fit to the data.
re s u l t s: Overall mean global methylation (± SD) was 26.3 ± 1.0 as meas  ured by Alu and 76.8 ± 1.9 
as measured by LINE-1. In the mixed-effects model, patella lead levels were inversely associated with 
LINE-1 (β = –0.25; p < 0.01) but not Alu (β = –0.03; p = 0.4). Tibia lead and blood lead did not pre-
dict global methylation for either Alu or LINE-1. 
co n c l u s i o n: Patella lead levels predicted reduced global DNA methylation within LINE-1   
elements. The association between lead exposure and LINE-1 DNA methylation may have implica-
tions for the mechanisms of action of lead on health outcomes, and also suggests that changes in 
DNA methylation may represent a biomarker of past lead exposure. 
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in global DNA methylation and that this 
association would be more evident than an 
association with a biomarker of concurrent/
short­term exposure such as blood lead.
Methods
This study was approved by the institutional 
review boards of Harvard School of Public 
Health, Brigham and Women’s Hospital, and 
the Boston Veteran’s Administration Hospital, 
and all participants gave written informed con­
sent. This study was conducted on a subsam­
ple of the Normative Aging Study (NAS), a 
multi  disciplinary longitudinal study of aging 
established by the Veterans Administration in 
1963 (Bell et al. 1966). Briefly, 2,280 men were 
enrolled in the NAS. Participants received their 
first medical examination between 1963 and 
1969. Subsequently, subjects have reported for 
medical examinations and standard blood and 
urine tests every 3–5 years. During those visits, 
NAS participants filled out questionnaires on 
smoking history, education level, food intake, 
and other risk factors that may influence health. 
Beginning in 1991, those who gave their 
informed consent presented to the Ambulatory 
Clinical Research Center of Brigham and 
Women’s Hospital for a K­X­ray fluorescence 
(KXRF) measurement of lead content in the 
tibia and patella. Study subjects were thus meas­
ured for bone lead between 1991 and 1999.
Bone lead levels measured by KXRF. Bone 
lead measurements were taken at two sites, 
the mid­tibial shaft and the patella, with an 
ABIOMED KXRF instrument (ABIOMED, 
Inc., Danvers, MA, USA, and the Harvard 
Metals Epidemiology Research Group) (Hu 
et al. 1990). The tibia and patella have been 
targeted for bone lead research because these 
two bones consist mainly of pure cortical and 
trabecular bone, respectively. A 30­min meas­
urement was taken at the midshaft of the left 
tibia and at the left patella after each region 
had been washed with a 50% solution of iso­
propyl alcohol. The tibial midshaft was taken 
as the point equi  distant between the tibial pla­
teau and the medial malleolus. The KXRF 
beam collimator was sited perpendicular to the 
flat bony surface of the tibia and at the patella.
As a quality­control measure, once a week 
a 15­ppm phantom was positioned and meas­
ured 20 consecutive times overnight as a first­
order calibration check. Analysis of means and 
SDs was performed to disclose any significant 
shift in accuracy or precision. Once a month, 
the entire set of calibration phantoms (0, 5, 
10, 15, 20, 30, 40, 50, and 100 ppm; true 
values checked by inductively coupled plasma­
mass spectrometry) was measured, and a cali­
bration curve was calculated as a final check 
on calibration.
Blood lead levels measured by graph-
ite atomic absorption spectrometry. Fresh 
blood for lead measurement was taken in a 
special lead­free tube containing EDTA and 
sent to ESA Laboratories, Inc. (Chelmsford, 
MA, USA). Blood samples were analyzed by 
a Zeeman background­corrected flameless 
atomic absorption spectrophotometer (graph­
ite furnace). The instrument was calibrated 
before use with National Institute of Standard 
and Technology materials. Ten percent of the 
samples were run in duplicate. In tests on ref­
erence samples from the Centers for Disease 
Control and Prevention, precision (% relative 
SD) ranged from 8% for concentrations < 30 
µg/dL to 1% for higher concentrations. Blood 
lead levels are measured at each triennial NAS 
study visit. For purposes of this study, we used 
the blood lead measurement most proximal in 
time to the bone lead measurement. 
DNA methylation. Bisulfite treatment. 
DNA was extracted from stored frozen buffy 
coat of 7 mL whole blood, using the QiAmp 
DNA blood kits (QIAGEN, Valencia, CA, 
USA); 500 ng DNA (50 ng/µL) was treated 
using the EZ DNA Methylation­Gold Kit 
(Zymo Research, Orange, CA, USA) according 
to the manufacturer’s protocol. Final elution 
was performed with 30 µL M­Elution buffer.
Polymerase chain reaction and pyro-
sequencing. DNA methylation was quanti­
tated using bisulfite­polymerase chain reaction 
(PCR) and pyro  sequencing, using primers and 
conditions described previously (Baccarelli 
et al. 2009; Colella et al. 2003; Tarantini et al. 
2009; Yang et al. 2004). We used LINE­1 
and Alu element PCR for pyrosequencing­
based methylation analysis following previously 
published methods (Bollati et al. 2007; Tost 
et al. 2003), with the following modifications: 
A 50­µL PCR was carried out in 25 µL GoTaq 
Green Master mix (Promega, Madison, WI, 
USA), 1 pmol biotinylated forward primer, 
1 pmol reverse primer, 50 ng bisulfite­treated 
genomic DNA, and water. A biotin­labeled 
primer was used to purify the final PCR prod­
uct using Sepharose beads. The PCR prod­
uct was bound to Streptavidin Sepharose HP 
(Amersham­Biosciences, Uppsala, Sweden), 
and the Sepharose beads containing the immo­
bilized PCR product were purified, washed, 
denatured using a 0.2­M NaOH solution, 
and washed again using the Pyrosequencing 
Vacuum Prep Tool (Pyrosequencing Inc., 
Westborough, MA), according to the manu­
facturer’s recom  mendations. Pyrosequencing 
primer (0.3 µM) was then annealed to the puri­
fied single­stranded PCR product, and pyrose­
quencing was performed using the Pyromark 
MD System (Pyrosequencing Inc.). The degree 
of methylation was expressed as the percentage 
of 5­methylated cytosines (%5mC) divided by 
the sum of methylated and unmethylated cyto­
sines. The assays, which allow for the ampli­
fication of a representative pool of repetitive 
elements, quantitatively assess the proportion of 
methylated sites in Alu and LINE­1 repetitive 
elements dispersed throughout the genome. 
Measures of Alu and LINE­1 methylation 
are highly correlated with 5­methyl  cytosine 
content measured through high­performance 
liquid chromatography and have been widely 
used as a surrogate of global methylation 
(Weisenberger et al. 2005; Yang et al. 2004). 
We used non­CpG cytosine residues as built­in 
controls to verify bisulfite conversion. Each 
sample was tested in two replicates, and their 
average was used in the statistical analysis.
Statistical analysis. We excluded tibia 
and patella bone lead measurements with 
estimated uncertainties > 10 µg/g bone and 
> 15 µg/g bone, respectively, because these 
measurements usually reflect excessive patient 
movement during the measurement (Hu 
et al. 1998). Such procedures are standard in 
analysis of bone lead data (Aro et al. 1994). 
We used the generalized extreme studentized 
deviation many­outlier method (Rosner 1983) 
to remove extreme outliers among the con­
tinuous independent variables with a normal 
distribution, as performed in previous analyses 
(Carey et al. 1997; Hu et al. 1996; Rexrode 
et al. 1998; Whitsel et al. 2001). This proce­
dure removed 10 subjects with extreme tibia 
lead levels and 8 subjects with extreme patella 
lead levels. We also report results of analyses in 
which those subjects with extreme bone lead 
measurements were included.
Statistical analysis of predictors of DNA 
methylation levels. We fit a mixed­effects 
model to account for repeatedly meas  ured 
methylation levels. Analyses were performed to 
evaluate the association between lead biomark­
ers and DNA methylation levels. The potential 
confounding factors included were age, body 
mass index (BMI), percentage of lymphocytes 
among white blood cells (WBCs), education, 
and pack­years of cigarettes. Blood lead levels 
were used as the index of lead exposure in a 
separate model. Adjustment for confounders 
was conducted in stages to identify which con­
founders had a strong influence on results. A 
random slope for the time elapsed from the 
first visit for DNA methylation was initially 
considered to account for subject–specific vari­
ability of methylation over time, but a random­
intercept­only model was preferred based on 
the likelihood ratio test comparing the two 
models. We also examined whether the asso­
ciation between bone lead and global DNA 
methylation levels changed over time. We 
included an interaction term between the time 
elapsed from the first visit and each bone lead 
marker, but we did not see any statistically sig­
nificant interaction. Therefore, we eliminated 
this interaction term from the final model. The 
following equation describes the structure of 
our fitted models: 
Yij = (b0 + ui) + covariates + b1Timeij  
  + b2BonePbij + eij [1], Wright et al.
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where Yij is the methylation levels (Alu or 
LINE­1) in subject i at time j, b0 is the overall 
intercept, ui is the separate random intercept 
for subject i, b1 is the slope representing the 
overall effect of time, and b2 is the slope rep­
resenting the overall effect of the bone lead 
marker. All mixed­effects models were con­
ducted using the PROC MIXED procedure 
in SAS, version 9.1 (SAS Institute Inc., Cary, 
NC, USA).
To determine whether the associations 
between DNA methylation levels and the 
different lead biomarker were non  linear, we 
also modeled the lead biomarker as a penal­
ized spline in a generalized additive models 
using R software (R Foundation for Statistical 
Computing; http://www.r­project.org).
Results
Between 1 March 1999 and 27 June 2007, 
1,047 blood samples from 704 subjects were 
successfully analyzed for DNA methylation in 
both Alu and LINE­1. Of these 704 subjects, 
168 did not have bone lead measurements, 
leaving 536 subjects available for analysis. 
Fourteen subjects with uncertainty > 10 g/g 
lead in bone for tibia or 15 g/g for patella 
were excluded, reducing this number to 
522 subjects available for the analysis. Finally, 
5 subjects with missing values in WBC dif­
ferentials were also excluded. Therefore, in the 
end, 517 subjects with a total of 787 observa­
tions were available for analysis.
Table 1 lists the demographic charac  teris­
tics of the population at baseline (i.e., at the 
first measurement of DNA methylation) and 
a comparison with those subjects who had 
bone lead data but did not supply DNA for 
methylation analysis. In general, subjects with 
and without methylation data were very simi­
lar with respect to the covariates. Table 2 pres­
ents the unadjusted relation  ships between lead 
biomarkers and global DNA methylation, 
as well as the relation  ship among the covari­
ates and bio  markers of global DNA methyla­
tion at baseline. Consistent with our previous 
report (Bollati et al. 2009), DNA methylation 
values for both Alu and LINE­1 decreased 
with increasing age (Table 3). Trends are sim­
ilar for increasing levels of patella lead, but no 
relation  ship is evident for either tibia or blood 
lead. A trend toward increased methylation at 
LINE­1 CpG islands was seen for both pack­
years of cigarette smoking and increasing years 
of education, but not for Alu (Table 2). 
In our mixed­effects models adjusting 
for smoking, age, BMI, education, and the 
percentage of lympho  cytes in the WBC dif­
ferential, we found that, again, patella lead 
levels were associated with decreasing levels 
of global DNA methylation in LINE­1 retro­
transposons but not with methylation at Alu 
elements (Table 3). We found no signifi­
cant association between either global DNA 
methyla  tion marker and blood or tibia lead 
levels. At baseline, LINE­1 methylation was 
inversely associated with age (Table 2). Finally, 
we generated a smoothed plot of the relation­
ship between patella lead levels and LINE­1 
element methyla  tion (Figure 1). This plot sug­
gests that the relationship may be non  linear, 
with the primary decrease occurring between 
Table 1. Summary statistics [mean ± SD or n (%)] at baseline for participants with and without bone lead 
measurements in the NAS.
Characteristic
With bone lead 
measure (n = 517)
Without bone lead 
measure (n = 162) p-Valuea
Tibia lead (g/g) 20.5 ± 14.8 —
Patella lead (g/g) 27.4 ± 19.7b —
Blood lead (µg/dL) 4.1 ± 2.4c 3.9 ± 2.1d 0.59
Alu (%) 26.3 ± 1.0 26.2 ± 1.2 0.27
LINE-1 (%) 76.8 ± 1.9 77.1 ± 2.1 0.16
Age (years) 72.4 ± 6.5 72.5 ± 7.6 0.95
BMI (kg/m2) 28.0 ± 3.8 28.5 ± 4.5 0.45
Lymphocytes (%) 25.5 ± 8.6 25.7 ± 7.2 0.56
Pack-years of cigarettes 20.1 ± 25.3 25.6 ± 32.7 0.02
Education 0.85
Less than high school diploma 46 (8.9) 10 (6.2)
High school diploma/some college 314 (60.7) 88 (54.3)
Four years of college 143 (27.7) 39 (24.1)
Missing 14 (2.7) 25 (15.4)
ap-Values for differences between subjects with and without bone lead measurements from Wilcoxon rank sum or 
Fisher’s exact test. bn = 508 for patella and 517 for tibia. cn = 463. dn = 127.
Table 2. Distribution of DNA methylation at baseline by categories of covariates.
Methylation (mean ± SD)
Variable n (%) Alu (%) LINE-1 (%)
Tibia lead (g/g)a
13.0 166 (32.1) 26.40 ± 0.95 77.01 ± 1.79
> 13.0 to 22 176 (34.0) 26.18 ± 1.02 76.64 ± 2.02
> 22 175 (33.9) 26.32 ±1.04 76.73 ± 1.74
p for trend 0.50 0.18
Patella lead (g/g)a
17.0 167 (32.9) 26.36 ± 1.03 77.17 ± 1.79
> 17.0 to 29 160 (31.5) 26.30 ± 0.91 76.61 ± 1.94
> 29 181 (35.6) 26.22 ± 1.07 76.57 ± 1.80
p for trend 0.19 0.003
Blood lead (g/dL)a
2.0 114 (24.6) 26.35 ± 0.85 76.97 ± 1.78
> 2.0 to 4.0 205 (44.3) 26.18 ± 0.95 76.68 ± 2.06
> 4.0 144 (31.1) 26.41 ± 1.16 76.78 ± 1.61
p for trend 0.52 0.44
Lymphocytes (%)a
21.0 165 (31.9) 26.26 ± 0.95 77.03 ± 1.88
> 21.0 to 28 186 (36.0) 26.39 ± 1.08 76.69 ± 1.64
> 28 166 (32.1) 26.23 ± 0.98 76.66 ± 2.05
p for trend 0.79 0.07
Age (years)
< 70 186 (36.0) 26.41 ± 0.97 77.05 ± 2.01
70–79 265 (51.3) 26.28 ± 1.03 76.64 ± 1.80
> 80  66 (12.8) 26.07 ± 1.01 76.65 ± 1.54
p for trend 0.02 0.04
BMI (kg/m2)
< 25 97 (18.8) 26.22 ± 0.98 76.74 ± 1.89
25–30 290 (56.1) 26.28 ± 0.94 76.72 ± 1.85
> 30  130 (25.1) 26.39 ± 1.16 76.97 ± 1.85
p for trend 0.21 0.31
Education
Less than high school 46 (9.2) 26.28 ± 1.05 76.07 ± 1.79
High school/some college 314 (62.4) 26.25 ± 0.97 76.85 ± 1.84
Four years of college 143 (28.4) 26.40 ± 1.09 76.88 ± 1.88
p for trend 0.25 0.06
Cigarette smoking (pack-years)
0 174 (33.7) 26.22 ± 0.99 76.67 ± 1.58
30 206 (39.8) 26.40 ± 1.09 76.71 ± 1.99
> 30 137 (26.5) 26.25 ± 0.89 77.05 ± 1.96
p for trend 0.68 0.09
aCategories are based on the tertile of the variable. Lead biomarkers and DNA methylation within retrotransposons
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patella lead levels between 0 and approximately 
40 µg/g bone and a leveling out of the effect at 
levels higher than this.
Discussion
Cumulative exposure to lead and DNA 
methyla  tion. In the present study we found 
an association between patella lead levels (a 
biomarker of cumulative lead exposure) with 
LINE­1 repetitive element methylation. Blood 
lead levels (a biomarker of recent exposure) 
were not associated with DNA methyla­
tion. Our group (Pilsner et al. 2009) recently 
reported an association between global DNA 
methylation in umbilical cord WBC DNA 
and maternal patella lead levels. Here we 
expand that work by studying an aging popu­
lation, as opposed to newborns and women 
of childbearing age. Our results suggest that 
cumulative past exposure to lead among 
elderly individuals is associated with decreased 
LINE­1 DNA methylation, even after adjust­
ing for age. This association is therefore likely 
due to the effects of distant past exposure, 
rather than more contemporaneous lead 
exposure. Our study popu  lation is composed 
of elderly men, the majority of whom were 
retired at the time of the study, limiting any 
impact of recent or sub  acute occupational lead 
exposure not captured by blood or bone lead.
Bone lead is a unique biomarker in that 
past exposures can be accurately reconstructed 
and their impact on health directly measured. 
Because of bone lead’s half life of ≥ 10 years, 
ultimately > 90% of body lead is found in 
bone (Leggett 1993). Few chemicals have 
such a well­established cumulative exposure 
biomarker. This may mean that bone lead is 
uniquely suited as a paradigm biomarker in 
which to test whether DNA methylation pat­
terns in WBCs correlate with lifetime envi­
ronmental exposures. However, because bone 
is not a uniform tissue, we measured lead in 
two types of bone: trabecular and cortical. 
Tibia represents cortical bone, and its matrix 
turnover is slower than trabecular bone, which 
is represented by patella (Hu et al. 1998). 
Previous research shows that tibia lead is bio­
logically more inert than patella lead but is a 
better dosimeter of cumulative exposure (Hu 
et al. 2007; Kosnett et al. 2007; Todd and 
Chettle 1994). This is reflected in the longer 
half­life of cortical lead levels (approximately 
12–15 years) relative to trabecular lead lev­
els (approximately 8–10 years). In general, 
the higher turn  over rate of patella bone lead 
into blood means that lead within trabecular 
bone is more biologically active (Hu et al. 
2007). This may explain why this particular 
biomarker was statistically associated with 
reduced methylation of LINE­1. Under the 
assumption that DNA­methylation changes 
in lymphocytes are most influenced by direct 
chronic exposure to circulating lead in blood, 
patella lead would be more likely to be associ­
ated with DNA methylation changes than 
tibia lead. Considering the differences in the 
kinetics of tibia and patella lead, the DNA 
methylation findings seen in this study sug­
gest that redistribution of lead from bone 
over time may be part of the mechanism by 
which patella lead is associated with reduced 
DNA methylation in LINE­1. If the associa­
tion were purely due to cumulative lead expo­
sure, one would expect tibia lead to be more 
strongly associated with DNA methylation 
than patella lead.
Global methylation markers. Changes 
in methylation patterns among markers of 
global methylation, such as LINE­1 and Alu, 
had been thought to represent a more passive 
response to environmental factors. Changes in 
methylation in these sequences could reflect 
the general impact of environmental fac­
tors on DNA methylation, as they were not 
believed to be functional and methylation 
would likely be less regulated compared with 
regions containing genes (Axume et al. 2007; 
Weisenberger et al. 2005). Such transposable 
elements comprise > 50% of DNA sequence 
and were initially believed to be nonfunc­
tional “junk” DNA. More recent work has 
demon  strated that they play a critical role in 
human development, tissue differentiation, 
and gene expression, as these elements can 
be transcribed and translated into functional 
proteins (Belancio et al. 2009; Han and Boeke 
2005). LINE­1 elements comprise about 20% 
of the human genome, are approximately 
6,000 base pairs long, and consist of two open 
reading frames, one of which codes for an 
enzyme with both endo  nuclease and reverse 
transcriptase properties (Garcia­Perez et al. 
2007; Wallace et al. 2008a, 2008b). Using 
this enzyme, LINE­1 elements can replicate 
and insert themselves into different genomic 
regions. Decreased methylation of LINE­1 
elements would be expected to lead to the 
transcriptional activation of those repetitive 
sequences that contain complete promoters 
(Wilson et al. 2007). The majority of LINE­1 
elements cannot be active because they have 
been either truncated or mutated over our 
evolutionary history. However, the human 
genome averages 500,000 LINE­1 copies, 
of which appproximately 3,000 LINE­1 
sequences are complete (Lander et al. 2001) 
and 200 are potentially transcribed (Brouha 
et al. 2003). This is still a large number of 
biologically active retro  transposons. If dem­
ethylation of these LINE­1 elements activates 
their transcription and they are inserted near 
or within genes, they can alter gene expression 
and ultimately cell function. Furthermore, 
LINE­1 elements regulate replication and 
insertion of short interspersed nuclear ele­
ments such as Alu. Alu insertion into genes 
can also regulate gene expression and/or func­
tion (Wallace et al. 2008a, 2008b). Such 
findings suggest that these retro  transposons 
may represent yet another level of epigenetic 
regulation of gene expression. Indeed, a grow­
ing body of evidence suggests that LINE­1 
transposition plays a critical role both in cell 
differentiation and in regulating the mam­
malian transcriptome (Coufal et al. 2009; 
Zemojtel et al. 2007). Changes in methyla­
tion of LINE­1 secondary to environment 
exposures may have significant impacts on 
health (Wallace et al. 2008a, 2008b; Wilson 
et al. 2007). Within this context, our finding 
Table 3. Cross-sectional lead biomarker association with DNA methylation estimated from mixed-effects 
models with increasing adjustment for confounders.
Alu β (95% CI) LINE-1 β (95% CI)
Tibia lead (IQR = 15 g/g)
Model 1 (n = 787) 0.01 (–0.08 to 0.10) –0.11 (–0.28 to 0.05)
Model 2 (n = 762) 0.01 (–0.09 to 0.11) –0.06 (–0.23 to 0.12)
Model 3 (n = 694) 0.02 (–0.10 to 0.13) –0.07 (–0.29 to 0.14)
Patella lead (IQR = 19 g/g)
Model 1 (n = 772) –0.01 (–0.10 to 0.07) –0.20 (–0.36 to –0.05)* 
Model 2 (n = 747) –0.01 (–0.10 to 0.08) –0.17 (–0.33 to 0.00)* 
Model 3 (n = 679) –0.03 (–0.14 to 0.08) –0.25 (–0.44 to –0.05)* 
Blood lead (IQR = 2 g/dL)
Model 1 (n = 716) 0.03 (–0.04 to 0.11) –0.01 (–0.15 to 0.13)
Model 2 (n = 694) 0.03 (–0.05 to 0.10) 0.04 (–0.10 to 0.19)
Abbreviations: CI, confidence interval; IQR, interquartile range. Model 1 was adjusted for age, BMI, and percent lympho-
cytes; model 2 was adjusted for age, BMI, percent lymphocytes, education, and pack-years of cigarettes; and model 3 
was adjusted for for age, BMI, percent lymphocytes, education, pack-years of cigarettes, and blood lead levels. 
*p ≤ 0.05; n for each model represents total observations rather than individuals. 
Figure 1. Penalized spline showing nonlinear 
relation  ship between patella lead level and LINE-1 
DNA methylation. The plot is adjusted for age, BMI, 
education, WBC differential, and pack-years of 
smoking. 
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that bone lead levels are associated with lower 
LINE­1 element DNA methylation may 
have direct, rather than indirect, implica­
tions for the mechanistic role of lead exposure 
on health during aging. Future work target­
ing methyla  tion at specific, intact LINE­1 
sequence is needed to test this possibility.
Use of DNA methylation changes in WBCs 
as a biomarker. The growing interest in epi­
genetic biomarkers is due to their potential to 
explain fetal origins of disease or, even more 
broadly, to explain the latency between expo­
sure to toxic substances and subsequent disease 
phenotypes. Measures of DNA methylation 
hold substantial promise as a biomarker for 
toxic environmental exposures, but because 
such marks are specific to cell type, much 
work is still needed to determine what role, if 
any, WBC DNA methylation may have for 
diseases that occur in inaccessible target tis­
sues, such as the brain. Measuring target organ 
DNA methyla  tion would be ideal, but in many 
human studies obtaining such measures is not 
feasible. Nevertheless, peripheral WBC DNA 
methylation might hold promise as an exposure 
biomarker (as opposed to a biomarker of effect) 
by demon  strating that environmental factors 
can alter WBC DNA methylation patterns. 
LINE­1 and Alu are relatively primitive mark­
ers of global methylation because they are aver­
aged across thousands of repetitive sequences. A 
more specific epigenomic measure, such as pat­
terns of DNA methylation within gene­specific 
promoter sequences, might yield a more specific 
pattern quantifying past lead exposure. This 
finding raises the question of whether DNA 
methylation patterns could be a methodology 
to reconstruct past chemical exposure.
Recently, Chanda et al. (2006) observed 
significant hyper  methyla  tion of the p16 gene 
promoter in DNA from peripheral blood 
lymphocytes of subjects exposed to arsenic­
contaminated water, showing that DNA from 
peripheral blood cells may be a suitable tissue 
for the development of epigenetic biomark­
ers. An expansion of this concept (i.e., that 
gene­specific methylation is altered by envi­
ronment) to epigenomics may allow investiga­
tors to determine whether signature patterns 
of DNA methylation occur across the WBC 
epigenome that are specific to exposure to 
certain types of chemicals. This is effectively 
the concept under  lying the field of proteom­
ics. Epigenomics, because its marks are stable 
but modifiable and because the technology is 
already highly developed, may be an alterna­
tive means for such biomarker development. 
Because WBCs are not a target for many 
diseases, changes in DNA methyla  tion from 
peripheral blood cells may not reflect mecha­
nistic pathways in the target tissue. However, 
our results suggest that WBC DNA methyla­
tion may be useful as a biomarker of expo­
sure, possibly allowing investigators to confirm 
whether exposures are chronic versus short 
term. Given that exposure assessment is the 
“Achilles heel” of environ  mental epidemiol­
ogy, particularly with respect to case–control 
studies of chronic disease, the potential for 
epigenetic or epigenomic marks to establish or 
confirm the presence or chronicity of environ­
mental exposures deserves further study.
Limitations and future research. Our 
understanding of the role of DNA methyla­
tion and other epigenetic marks on gene 
expression and disease is clearly rudimentary 
at this stage. It is difficult therefore to ascribe 
the direct consequences of our findings to 
specific lead­associated health effects. We 
believe that epigenetic marks may play a sig­
nificant role in the biological pathway from 
environ  mental exposures to disease and health 
states, and perhaps are critical to explaining 
the long latencies often observed between lead 
exposure and health effects. However, we also 
believe that to fully interpret such data, we 
must first establish norms and whenever possi­
ble study the target organ directly, rather than 
WBCs. Unlike DNA sequence, for which a 
large inventory of data has established a con­
sensus baseline sequence, there is no blueprint 
of what are “normal” DNA methylation pat­
terns. Such an inventory will be complex, as it 
is cell type–specific and will also change with 
different life stages. Establishing baseline pat­
terns of methyla  tion across the epi  genome in 
tissues readily accessible to researchers (e.g., 
blood, saliva, buccal cells) will be critical 
to understanding the relationship between 
environmental exposures, DNA methylation 
changes, and health. Because methylation pat­
terns are not inert, inventories will need to 
account for changes in methylation patterns 
specific to life stages. Work conducted con­
currently in animal models may also allow us 
to better understand how changes in WBC 
DNA methylation in response to environ­
mental stimuli correlate to changes in target 
tissues/cells that are not readily accessible, 
such as brain regions. In summary, we have 
found that LINE­1 DNA methylation is 
inversely associated with patella lead levels in 
a population of elderly men. Our work sug­
gests that changes in DNA methylation may 
be part of the under  lying biological pathway 
between lead exposure and multiple lead­as­
sociated health effects. There are many caveats 
to our findings, including whether findings 
in WBC DNA are representative of target 
tissue changes and whether the association 
of lead with decreased LINE­1 methylation 
is functional or merely representative of the 
impact of lead on DNA methylation glob­
ally. Despite these limitations, we believe that 
a better understanding of epi  genetic marks 
as they relate to environmental exposure is 
critical to our understanding of human health 
and development. Future work is needed to 
establish baseline norms for epigenetic marks, 
to establish whether specific environmental 
exposures alter such marks, to determine 
whether WBC DNA methyla  tion changes 
correlate with target tissue changes, and 
finally, to determine whether such changes are 
part of the causal pathway between environ­
ment and disease.
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